CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 022249/S-19

Trade Name: **TREANDA**

Generic Name: **Bendamustine Hydrchloride**

Sponsor: **Cephalon, Inc.**

Approval Date: 03/10/2015

Indications: TREANDA is an alkylating drug indicated for treatment of patients with :

- Chronic Lymphocytic Leukemia (CLL)
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022249/S-19

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	
Labeling	**X**
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Other Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022249/S-19

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022249/S-019

SUPPLEMENT APPROVAL

Cephalon, Inc. (a wholly owned subsidiary of Teva Pharmaceuticals, Ltd.)
Attention: Michael J. McGraw, PharmD, MS
Director, Regulatory Affairs
41 Moores Road
P.O. Box 4011
Frazer, PA 19355

Dear Dr. McGraw:

Please refer to your Supplemental New Drug Application (sNDA) dated March 6, 2015, received March 6, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TREANDA® (bendamustine hydrochloride) Injection (solution) 45mg/0.5mL or 180mg/2mL, and TREANDA® (bendamustine hydrochloride) for Injection (lyophilized powder), 25 mg/vial or 100mg/vial.

We acknowledge receipt of your submissions related to this NDA dated February 26, March 2, 3, 4, and 6, 2015. We also acknowledge receipt of your amendments to this supplement on March 9 and 10, 2015.

This "Changes Being Effected" supplemental new drug application provides for updates to the Unites States Prescribing Information (USPI) to include both formulations, Treanda Injection (Solution) and Treanda for Injection (lyophilized powder). In addition, the label provides for additional information on the use of Treanda liquid formulation and incompatibilities with Closed System Transfer Devices (CSTD) that contains polycarbonate or acrylonitrile-butadiene-styrene (ABS).

We also have the following comments regarding this sNDA approval:

1. Submit quarterly reports until March 2017 of complaints about preparation and use of Treanda injection (solution) and Treanda for injection (lyophilized powder).

2. We remind you of your commitment to continue conducting device compatibility studies with Treanda injection (solution) to ensure safe preparation and use of Treanda injection (solution).

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Until carton labeling and vial changes are implemented, as an interim measure for the Treanda liquid product that has already been distributed to pharmacies, hospitals, etc., you need to provide stickers/labels that can adhere to the carton labeling with the Treanda liquid product. FDA recommends the following statement on the sticker: "**Not for use with devices that contain polycarbonate or acrylonitrile-butadiene-styrene (ABS)".** The sticker should be accompanied with the Dear Healthcare Provider (DHCP) letter. Furthermore, the same sticker should be attached to carton and any other appropriate labeling of already existing and ready for shipment product supply at the manufacturers and distributors sites.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.